<DOC>
	<DOCNO>NCT01967147</DOCNO>
	<brief_summary>The purpose study demonstrate superior efficacy Systane® Balance Preservative-Free 0.9 % Saline follow 35 day QID ( 4 time day ) dose treat dry eye subject lipid deficiency .</brief_summary>
	<brief_title>Clinical Outcomes Following Treatment With Systane® Balance Dry Eye Subjects</brief_title>
	<detailed_description>This study consist 4 visit conduct 3 sequential phase : Run-in Phase ( include screen visit run-in period ) , Treatment Phase I Treatment Phase II . In Phase I , subject randomize either Systane® Balance Saline dose 4 time day 35 day . In Phase II ( Day 35-90 ) subject continue dose assigned product as-needed basis .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Must follow least 1 eye Screening : 1 . Meibomian Gland Dysfunction ( MGD ) grade Expressibility ≤ 2 Meibum Quality ≤ 2 , 2 . The average 3 measure TFBUT ≤ 5 second , 3 . Unanesthetized Schirmer I test ≥ 3 mm . Must Ocular Surface Disease Index ( OSDI ) Score ≥ 18 Visit 1 prior randomization ( ie , 2 week runin PreservativeFree 0.9 % Saline administer 4 time day ) . Must bestcorrected visual acuity 55 letter well eye assess use early treatment diabetic retinopathy study ( ETDRS ) chart ( letter read method ) . Physician diagnosis dry eye least 6 month prior Screening visit . Willing able attend study visit . Must sign write informed consent form . Other protocoldefined inclusion criterion may apply . Subjects topical ocular treatment contain benzalkonium chloride ( BAK ) , product know toxicity corneal surface , within 30 day Screening . Subjects start , stop , change lid hygiene regimen within 30 day Screening . Use artificial tears/lubricants/gels/rewetting drop within 4 hour Screening . Women childbearing potential exclude participate study meet follow condition : Currently pregnant , Test positive pregnancy Screening visit , Currently breast feeding , Are agreement use adequate birth control method prevent pregnancy throughout study . Hypersensitivity use study product allergy ingredient study product . Has active ocular allergy . Any ocular abnormality could adversely affect safety efficacy outcome , include eyelid anomaly , corneal disorder , history herpes simplex , etc . Subjects take systemic medication know cause dry eye unless stable therapy/dosage least 30 day prior Screening remain stable dosage duration study . History ocular intraocular surgery ( include periocular Botox injection ) , eyelid surgery , keratorefractive procedure , corneal transplant variant , serious ocular trauma within 1 year Screening . Active ocular infection ( bacterial , viral fungal ) , active inflammation associate dry eye uveitis , iritis , active blepharitis , active allergic conjunctivitis , etc . Subjects punctal plug insertion diathermy procedure initiate within 30 day Screening . Any significant illness could expect interfere study parameter . Subjects active oculodermal rosacea meibomian gland dysfunction . Participation investigational drug device trial within 30 day Screening . Contact lens use within 30 day prior Screening , unwilling avoid contact lens use course study . Unwilling avoid use additional artificial tears/lubricants/gels/rewetting drop ( assign study medication ) throughout course study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Dry eye</keyword>
	<keyword>Lipid deficiency</keyword>
	<keyword>Tear film break-up time</keyword>
</DOC>